Tebentafusp’s mechanism—redirecting polyclonal T cells to gp100-expressing melanoma cells—triggers robust immune activation, as demonstrated by skin biopsies showing infiltration of CD8+ cytotoxic T cells, upregulation of interferon-γ (IFN-γ), and granzyme B in cutaneous lesions (30). The gene discussed is PMEL; the disease is melanoma.